PortfoliosLab logo
PBE vs. IDNA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between PBE and IDNA is 0.58, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.0
Correlation: 0.6

Performance

PBE vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Invesco Dynamic Biotechnology & Genome ETF (PBE) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

-20.00%-10.00%0.00%10.00%20.00%30.00%40.00%NovemberDecember2025FebruaryMarchApril
20.09%
-14.50%
PBE
IDNA

Key characteristics

Sharpe Ratio

PBE:

-0.00

IDNA:

-0.31

Sortino Ratio

PBE:

0.14

IDNA:

-0.28

Omega Ratio

PBE:

1.02

IDNA:

0.97

Calmar Ratio

PBE:

-0.00

IDNA:

-0.11

Martin Ratio

PBE:

-0.01

IDNA:

-0.77

Ulcer Index

PBE:

6.53%

IDNA:

9.68%

Daily Std Dev

PBE:

21.29%

IDNA:

24.19%

Max Drawdown

PBE:

-45.69%

IDNA:

-68.26%

Current Drawdown

PBE:

-27.03%

IDNA:

-62.06%

Returns By Period

In the year-to-date period, PBE achieves a -8.14% return, which is significantly higher than IDNA's -9.77% return.


PBE

YTD

-8.14%

1M

-5.87%

6M

-8.93%

1Y

2.12%

5Y*

2.69%

10Y*

1.27%

IDNA

YTD

-9.77%

1M

-2.58%

6M

-14.28%

1Y

-6.05%

5Y*

-8.43%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


PBE vs. IDNA - Expense Ratio Comparison

PBE has a 0.59% expense ratio, which is higher than IDNA's 0.47% expense ratio.


Expense ratio chart for PBE: current value is 0.59%, compared with the broader market range of 0.00% to 2.12%.0.50%1.00%1.50%2.00%
PBE: 0.59%
Expense ratio chart for IDNA: current value is 0.47%, compared with the broader market range of 0.00% to 2.12%.0.50%1.00%1.50%2.00%
IDNA: 0.47%

Risk-Adjusted Performance

PBE vs. IDNA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PBE
The Risk-Adjusted Performance Rank of PBE is 1919
Overall Rank
The Sharpe Ratio Rank of PBE is 1919
Sharpe Ratio Rank
The Sortino Ratio Rank of PBE is 2020
Sortino Ratio Rank
The Omega Ratio Rank of PBE is 1919
Omega Ratio Rank
The Calmar Ratio Rank of PBE is 1919
Calmar Ratio Rank
The Martin Ratio Rank of PBE is 1919
Martin Ratio Rank

IDNA
The Risk-Adjusted Performance Rank of IDNA is 99
Overall Rank
The Sharpe Ratio Rank of IDNA is 88
Sharpe Ratio Rank
The Sortino Ratio Rank of IDNA is 88
Sortino Ratio Rank
The Omega Ratio Rank of IDNA is 99
Omega Ratio Rank
The Calmar Ratio Rank of IDNA is 1212
Calmar Ratio Rank
The Martin Ratio Rank of IDNA is 88
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

PBE vs. IDNA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Invesco Dynamic Biotechnology & Genome ETF (PBE) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for PBE, currently valued at -0.00, compared to the broader market-1.000.001.002.003.004.00
PBE: -0.00
IDNA: -0.31
The chart of Sortino ratio for PBE, currently valued at 0.14, compared to the broader market-2.000.002.004.006.008.00
PBE: 0.14
IDNA: -0.28
The chart of Omega ratio for PBE, currently valued at 1.02, compared to the broader market0.501.001.502.002.50
PBE: 1.02
IDNA: 0.97
The chart of Calmar ratio for PBE, currently valued at -0.00, compared to the broader market0.002.004.006.008.0010.0012.00
PBE: -0.00
IDNA: -0.11
The chart of Martin ratio for PBE, currently valued at -0.01, compared to the broader market0.0020.0040.0060.00
PBE: -0.01
IDNA: -0.77

The current PBE Sharpe Ratio is -0.00, which is higher than the IDNA Sharpe Ratio of -0.31. The chart below compares the historical Sharpe Ratios of PBE and IDNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.502.00NovemberDecember2025FebruaryMarchApril
-0.00
-0.31
PBE
IDNA

Dividends

PBE vs. IDNA - Dividend Comparison

PBE's dividend yield for the trailing twelve months is around 0.07%, less than IDNA's 1.09% yield.


TTM20242023202220212020201920182017201620152014
PBE
Invesco Dynamic Biotechnology & Genome ETF
0.07%0.05%0.02%0.00%0.00%0.04%0.00%0.00%0.57%0.38%1.12%0.55%
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
1.09%0.98%1.04%0.54%0.70%0.26%0.80%0.00%0.00%0.00%0.00%0.00%

Drawdowns

PBE vs. IDNA - Drawdown Comparison

The maximum PBE drawdown since its inception was -45.69%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for PBE and IDNA. For additional features, visit the drawdowns tool.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%NovemberDecember2025FebruaryMarchApril
-27.03%
-62.06%
PBE
IDNA

Volatility

PBE vs. IDNA - Volatility Comparison

The current volatility for Invesco Dynamic Biotechnology & Genome ETF (PBE) is 12.41%, while iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a volatility of 13.40%. This indicates that PBE experiences smaller price fluctuations and is considered to be less risky than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


4.00%6.00%8.00%10.00%12.00%14.00%NovemberDecember2025FebruaryMarchApril
12.41%
13.40%
PBE
IDNA